Scancell to list on Nasdaq after reverse merger with Neuphoria, funds $89M for melanoma immunotherapy trial

Scancell announced that it will become a publicly traded company on Nasdaq after completing an all‑stock reverse merger with Neophobia Therapeutics. The transaction gives Scancell a new ticker, SCLT, and resolves the shareholder situation for Neophobia, which halted its social anxiety program last year.

The deal includes $89 million in combined debt and equity financing. Scancell said the capital will support its global phase 3 trial of iSCIB1+, an immunotherapy targeting advanced melanoma that already carries fast‑track status from the FDA.

Phase 2 data from the Scope study showed a 77% progression‑free survival rate at 22 months when iSCIB1+ was used together with Bristol Myers Squibb’s Yervoy and Opdivo. The company expects additional data later this year and plans to advance the product into a registrational randomized study.

Management believes the merger and funding position Scancell to sustain operations through 2029 and to accelerate development of its lead asset, potentially expanding treatment options for melanoma patients.